Clinical Trial Update: Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining whether delaying Inmazeb (REGN-EB3) administration relative to Ervebo vaccination alters Ebola vaccine immune response in healt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ervebo (rVSVΔG-ZEBOV-GP)
• INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, and ODESIVIMAB-EBGN)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Ebola Virus Disease | Phase 2 | Status: NOT_YET_RECRUITING